Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Koji Haratani"'
Autor:
Shuta Tomida, Takashi Ogura, Tadashi Ishida, Shigeki Shimizu, Hidetoshi Hayashi, Koji Haratani, Masayuki Takeda, Junko Tanizaki, Ryoji Kato, Kohsuke Isomoto, Yasutaka Chiba, Akihiko Ito, Kazuhiko Nakagawa, Takashi Niwa, Kaoru Tanaka, Yasushi Fukuda, Toshihide Yokoyama
Publikováno v:
Clinical Cancer Research. 26:2037-2046
Purpose: The impact of EGFR tyrosine kinase inhibitors (TKI) on the tumor immune microenvironment (TME) in non–small cell lung cancer (NSCLC) is unclear. Experimental Design: We retrospectively identified 138 patients with EGFR-mutated NSCLC who un
Autor:
Masayuki Takeda, Kaoru Tanaka, Kimio Yonesaka, Koji Haratani, Hidetoshi Hayashi, Kazuko Sakai, Takayuki Takahama, Ryoji Kato, Kazuto Nishio, Kazuhiko Nakagawa
Publikováno v:
Lung Cancer. 139:28-34
Objectives The T790M secondary mutation of epidermal growth factor receptor gene (EGFR) is the most common mechanism of acquired resistance to first- or second-generation EGFR tyrosine kinase inhibitors (TKIs). We investigated the association between
Autor:
Osamu Nishiyama, Hidetoshi Hayashi, Akiko Sano, Yuji Tohda, Yusaku Nishikawa, Takashi Oomori, Kazuhiko Nakagawa, Shigeki Shimizu, Ryo Yamazaki, Kosuke Isomoto, Koji Haratani, Junko Tanizaki
Publikováno v:
BMC Pulmonary Medicine
BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-8 (2021)
Background The utility of bronchoscopy for patients with suspected immune checkpoint inhibitor (ICI)-related pneumonitis is currently debatable. The purpose of this study was to examine the findings of bronchoalveolar lavage (BAL) analysis and transb
Autor:
Kimio Yonesaka, Kazuhiko Nakagawa, Koji Haratani, Yoshikane Nonagase, Masayuki Takeda, Tomoaki Hoshino, Hidenobu Ishii, Koichi Azuma, Kaoru Tanaka, Hidetoshi Hayashi
Publikováno v:
Thoracic Cancer, Vol 10, Iss 10, Pp 1928-1935 (2019)
Thoracic Cancer
Thoracic Cancer
Background Non-small cell lung cancer (NSCLC) positive for activating mutations of the epidermal growth factor receptor (EGFR) gene is initially sensitive to EGFR-tyrosine kinase inhibitors (TKIs) but eventually develops resistance to these drugs. Up
Autor:
Masayuki Takeda, Yosuke Makuuchi, Junko Tanizaki, Kaoru Tanaka, Kazuhiko Nakagawa, Hidetoshi Hayashi, Kazuko Sakai, Kazuto Nishio, Shigeki Shimizu, Akihiko Ito, Koji Haratani
Publikováno v:
Oncotarget
The second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) alectinib and ceritinib are standard treatment options for patients with non–small cell lung cancer (NSCLC) positive for ALK fusion genes. However, almost all
Autor:
Kaoru Tanaka, Hidetoshi Hayashi, Kazuko Sakai, Masayuki Takeda, Kazuhiko Nakagawa, Kazuto Nishio, Koji Haratani, Takayuki Takahama, Junko Tanizaki
Publikováno v:
Oncotarget
Unlike common epidermal growth factor receptor gene (EGFR) mutations that confer sensitivity to tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC), mutations in exon 20 of either EGFR or the human EGFR2 gene (HER2) are associated
Autor:
Hidetoshi Hayashi, Kazuko Sakai, Shinobu Hosokawa, Motoko Tachihara, Shota Omori, Satoru Miura, Yuichi Ozawa, Kazumi Nishino, Shunichi Sugawara, Nobuyuki Yamamoto, Satoshi Hara, Keiichi Ota, Kazuhiko Nakagawa, Yasutaka Chiba, Kazuto Nishio, Koichi Azuma, Junko Tanizaki, Koji Haratani, Yasushi Fukuda, Yuki Sato
Publikováno v:
Journal of Clinical Oncology. 39:9037-9037
9037 Background: Although the efficacy of antibodies to programmed cell death–1 (PD-1) appears to be less pronounced in patients with NSCLC harboring epidermal growth factor receptor gene ( EGFR) mutations, patients who develop disease progression
Autor:
Shoichi Ohwada, Kimio Yonesaka, Hironori Yamada, Hidetoshi Hayashi, Tsutomu Iwasa, Toshio Shimizu, Emi Kamiyama, Kazuhiko Nakagawa, Koji Haratani
Publikováno v:
Cancer Chemotherapy and Pharmacology
Background This phase 1 study evaluated the safety, tolerability, pharmacokinetics and efficacy of patritumab (U3-1287) Process 2, a new formulation of fully human anti-HER3 monoclonal antibody in combination with erlotinib, an epidermal growth facto
Autor:
Kenji Hirotani, Kazuko Sakai, Satomi Watanabe, Hisato Kawakami, Takashi Kagari, Naoyuki Maeda, Kazuhiko Nakagawa, Koji Haratani, Naoki Takegawa, Kimio Yonesaka, Yasutaka Chiba, Kazuto Nishio
Publikováno v:
Oncogene. 38(9)
EGFR tyrosine kinase inhibitors (TKIs) are standard therapy for EGFR-mutant non-small cell lung cancer (NSCLC); however, these tumours eventually acquire chemoresistance. U3-1402 is an anti-HER3 antibody-drug conjugate with a novel topoisomerase I in
Autor:
Yosuke Togashi, K. Tanimura, Kazuhiko Nakagawa, Kaoru Tanaka, Hidetoshi Hayashi, Kazuko Sakai, Ken-ichiro Hayashi, Kimio Yonesaka, Takayuki Takahama, Masayuki Takeda, Hiroyasu Kaneda, Takeshi Yoshida, Koji Haratani, Yoshikane Nonagase, Tetsuya Mitsudomi, Tae Tanaka, Tadashi Ishida, Hiroshige Yoshioka, Junko Tanizaki, Shuta Tomida, Kazuto Nishio, Yasutaka Chiba
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 28(7)
The efficacy of programmed death-1 blockade in epidermal growth factor receptor gene (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) patients with different mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) is un